Enspectra Health Inc. Secures $7.5M Series A Funding to Advance Breakthrough Non-Invasive Skin Cancer Detection Technology

VCBeat (WeChat ID: vcbeat) has learned that Enspectra Health, Inc., a company in the field of skin cancer pathology, recently completed a $7.5 million Series A financing round. The round was led by Tsingyuan Ventures, a California-based venture capital firm focused on the technology sector. Previously, Enspectra Health, Inc. had completed its Pre-A round of financing, which was invested in by Chongshan Capital.

Enspectra Health, Inc., incubated by the Fogarty Institute and headquartered in Mountain View, Silicon Valley, California, USA, was founded by a team with technological roots at Stanford University. The company’s independently developed handheld device, PathWand, captures instant images of cellular structures identical to those seen in stained histological slides through mere skin contact, enabling physicians to non-invasively, rapidly, and accurately identify cancer cells. This innovation reduces reliance on traditional needle aspirations and biopsies, allowing pathologists and clinicians to perform extensive, painless examinations of suspicious skin lesions at early stages. Furthermore, this technology offers significant benefits for aesthetic dermatology and intraoperative pathological diagnosis.

Gabriel Sanchez, Co-founder and CEO of Enspectra Health, stated, “We have been seeking opportunities to scale our company, and Qingyuan Capital is the ideal partner. Their extensive experience in early-stage investment and medical technology will help drive new trends in digital imaging within the healthcare sector.” The funding will be used for product development, clinical data trials, subsequent FDA approval, and expanding the company’s team.

During its seed stage, Enspectra received funding and support from the U.S. National Cancer Institute. It also attracted Pre-A round investments from numerous prominent venture capital firms, including Chongshan Capital, F-Plant, and Konica. Subsequently, Enspectra conducted a clinical prototype trial at El Camino Hospital in Silicon Valley. The study results demonstrated that its independently developed device can effectively image skin across different ethnicities and age groups, and generate real-time images of cancerous tumor cells without the need for biopsy.

“We see tremendous opportunities in this emerging wave of digitalization,” said Gabriel Sanchez. “Our physician-researcher team is working diligently to digitize all histopathology slides, while our new technology enables us to generate real-time, non-invasive in vivo histological images. Furthermore, the implementation of image classification techniques will allow us to deliver superior services, with our ultimate goal being to help physicians detect skin cancer earlier, painlessly, and rapidly.”

New Vision Ventures is an investment firm focused on the healthcare sector. Its fund management team comprises seasoned industry professionals with robust capabilities in resource integration and post-investment management, with offices in Beijing and Silicon Valley. The New Vision Far-Sight Healthcare Fund, a RMB-denominated fund under New Vision Ventures, specializes in early-stage investments in the healthcare sector. It is dedicated to identifying and nurturing China’s most outstanding and high-growth healthcare entrepreneurial teams and enterprises, driving the development and transformation of the healthcare industry through an “industry plus capital” model.